24 Jun 2021
Approval Daratumumab in combination with Pomalidomide and Dexamethasone
The European Myeloma Network EMN is happy to announce the approval of Daratumumab in combination with Pomalidomide and Dexamethasone in Multiple Myeloma. This trial was performed by EMN under the guidance of Professor M. Dimopoulos from Greece as principal investigator. The approval opens the way to using this very effective combination in patients who have become refractory to at least 2 prior lines of therapy. We thank all investigators, participants and collaborators, the Janssen company and our patients for their contributions.
The official text and label for the approval is: “Daratumumab SC now is approved in combination with pomalidomide and dexamethasone (D-Pd) for the treatment of adults with multiple myeloma (MM) who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or after the last therapy.”